English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Hypoxia-ischemia is a dreaded cause of perinatal neurologic injury. Despite advances in maternal-fetal medicine and great strides in prevention, moderate to severe hypoxic-ischemic encephalopathy (HIE) of the newborn baby still occur every 1-2 per 1000 live births. Until very recently the management of such infants largely involves supportive care for major organ dysfunctions. Intensive research in both animals and subsequently humans over the past 3 decades has convincingly shown that induced systemic hypothermia, in which an infant’s body temperature is kept at 33,50C starting within 6 hours of birth and maintained for 72 hours, is effective in improving neurological outcome for infants with HIE. This therapy has thus become standard of care since 2010 [1, 2, 3]. Unfortunately even after treatment with induced hypothermia, a significant proportion of HIE infants still has neurological disabilities of varying degrees when assessed at 2 years of age [4]. Research thus continues in the quest for other modalities that will further improve outcomes.

Autologous umbilical cord blood cells for newborn infants with hypoxic-ischemic encephalopathy